To assess treatment-induced changes of intratumoral CD8+ T cells in an unbiased manner, CD8+ TILs from T3 sarcomas were analyzed using single-cell RNA-sequencing (scRNA-seq) 2 or 4 days after therapy with CD8-mIL2, CTRL-not-α-mIL2, anti–PD-1, or combinations thereof (Fig. 6A). The gene discussed is CD8A; the disease is sarcoma.